Allergan trims fat to halt takeover

Share this article:

Allergan is trimming the fat as part of efforts to head off a possible takeover by Valeant, two sources confirmed to Bloomberg. The company's restructuring plan is thought to include company-wide cost cuts, including some “legacy expenses,” the news service reported.

Allergan has rebuffed Valeant's last three offers since April, saying the offers do not reflect Allergan's value. Allergan CEO David Pyott set a five-year plan for cost-cutting targets in motion after the company rejected Valeant's initial bid.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.